Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1928MR)

This product GTTS-WQ1928MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species synthetic construct
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1928MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11979MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ7189MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ6214MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ12123MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ3407MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ4485MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ11493MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ5742MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW